Drug-eluting beads-transcatheter arterial chemoembolization with or without iodine-125 treatment is effective and tolerable in treating advanced non-small cell lung cancer patients: a pilot study

Abstract

Background This study aimed to explore the efficacy and safety of drug-eluting beads-transcatheter arterial chemoembolization (DEB-TACE) with or without iodine-125 ( 125 I) seed implantation in treating advanced non-small cell lung cancer (NSCLC) patients. Methods A total of 25 advanced NSCLC patients underwent DEB-TACE were consecutively enrolled, among which 17 cases also received 125 I seed implantation post DEB-TACE treatment. Treatment response, overall survival (OS), biochemical indexes and safety profiles were recorded and analyzed. Results Zero (0.0%), 13 (54.2%), 9 (37.5%) and 2 (8.3%) patients realized complete response (CR), partial response (PR), stable disease (SD) and progression disease (PD) respectively, and the objective response rate (ORR) and disease control rate (DCR) were 54.2% and 91.7%. The median OS was 12.6 (95% CI: 7.8–17.5) months. No difference of treatment response or OS was observed between DEB-TACE treatment alone and DEB-TACE plus 125 I seed implantation. Predictive factors analysis revealed that tumor size correlated with worse OS. Besides, chest distress grade and dyspnea grade were decreased after DEB-TACE procedure, while clinical symptoms were not changed after 125 I seed implantation. The common adverse events (AEs) were fever (32.0%), pain (12.0%) by DEB-TACE treatment, and common AE was pain (26.7%) by 125 I seed implantation. Conclusions DEB-TACE with or without 125 I seed implantation is effective and tolerable in treating advanced NSCLC patients.

Clinical outcomes of vinorelbine loading CalliSpheres beads in the treatment of previously treated advanced lung cancer with progressive refractory obstructive atelectasis

“…This treatment could control disease progression and contribute to pulmonary re-expansion over a relatively long period of time ( Shang et al, 2020 ). Improvement of dyspnea would elevate patient quality of life and strengthen confidence for patients with advanced lung cancer after failure of various therapies ( Zhao et al, 2020 ). Comparing the high pulmonary re-expansion rate after airway stent placement as the previous study reported, DEB-BACE would achieve effective pulmonary re-expansion, and meanwhile still locally control tumor growth ( Bi et al, 2020 ).…”

Image-Guided Percutaneous and Transarterial Therapies for Primary and Metastatic Lung Cancer

“…Moreover, the use of DEB-TACE, which employs the use of microspheres to not only serve as carriers of chemotherapy but also as embolization agents, has been shown to be effective in safe in patients with metastatic lung cancer and advanced NSCLC. 91 , 92 A recent retrospective study analyzed 36 patients with lung cancer and hemoptysis who were treated by either DEB-BACE or conventional BACE (cBACE). 68 The analysis found that while there were no significant differences in the technical and clinical successes of hemoptysis treatment ( P > .050), DEB-BACE was associated with increased total clinical response ( P = .021), greater objective response rate ( P = .035), and greater hemoptysis relapse-free survival ( P = .013) when compared to cBACE.…”